The company invests in and manages road and highway infrastructure projects, earning revenue through government annuity payments and toll collections via various special purpose vehicles.
The business lacks a competitive moat as evidenced by massive net margins of -4157% and the loss of major assets like Indore Dewas Tollways and Sai Maatarini Tollways to insolvency and termination. While regulatory licenses provide a theoretical entry barrier, the inability to cover interest costs or maintain equity value contradicts any structural advantage.
Capital allocation has been disastrous, characterized by the total erosion of net worth and the loss of control over material subsidiaries to lenders. Reinvestments in projects like Sai Maatarini resulted in massive write-offs following project termination and failed settlement negotiations.
The investment collapsed as the 'going concern' warning materialized into a total liquidation. The company's remaining equity was wiped out when lenders seized the final operational assets to satisfy defaulted debts that management had failed to even properly account for in their financial statements. The insolvency of the parent entity, Gayatri Projects, removed any hope of a bailout, leaving shareholders with worthless paper in a shell company that possessed no assets, no cash flow, and no path to recovery.
RichFakir rates Gayatri Highways Ltd's business quality as poor — 14/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Gayatri Highways Ltd is trading about 98% below our estimate of fair value; we rate its price cheap. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Gayatri Highways Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Gayatri Highways Ltd's fair value is about ₹81 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →